Core Insights - Abivax SA, a clinical-stage biotechnology company, reported its key financial information for Q3 2024, highlighting its focus on developing therapeutics for chronic inflammatory diseases [1][3] Financial Highlights - As of September 30, 2024, Abivax had cash and cash equivalents of EUR 180.5 million, which is expected to fund operations into Q4 2025 [3] - The total principal debt outstanding was EUR 106.3 million, a decrease from EUR 108.4 million as of June 30, 2024 [3][4] Business Updates - Abivax has made significant progress in its clinical trials, including the Phase 3 trial of its lead drug candidate, obefazimod, for ulcerative colitis [2][5] - The company has provided updates on various operational goals and milestones achieved in recent months, including enrollment milestones and interim efficacy results [2]
Abivax presents third quarter 2024 key financial information